BRCA ... Rubraca?

[pjoshea13]

"The FDA has said that phase 2 data suggest the drug could represent a new therapy option for men whose cancer has progressed despite chemotherapy, and treatment with androgen receptor therapy such as Pfizer/Astellas’ Xtandi (enzalutamide), or Johnson & Johnson’s Zytiga (abiraterone)."

pharmaphorum.com/news/fda-s...

fiercepharma.com/marketing/...

-Patrick

[snoraste]

Thanks for the post. I'll be looking for the TRITON announcement. I think as promising as these drugs are, as a monotherapy, they have limited effectiveness which is measured in months (median). It would be more interesting to see them combined with another agent, such as PD-1 (there are some clinical trials ongoing). There's already proof of Zytiga plus Olaparib combo (from your link):

fiercepharma.com/pharma/par...

I was offered the above combo by one MO, but decided not to opt for it because I feel the benefits maybe limited, and having spoken to a few Onc's, the new agents (PD/PDL-1) may hold a better promise.

recombo/BRCA group here are definitely benefiting from large crossover works getting done in Breast and Ovarian.